Jacqualine Gervais
Psychiatric/Mental Health · Moorhead, MNNPI 1336481803
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,425 of the $29,354 with a category attached, or 79.8%. AbbVie accounts for 96.1% of it on its own, with 8 other manufacturers making up the rest. Among psychiatric/mental health clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 83 payments — averaging $353.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$28K
- Johnson & Johnson$516
- Axsome Therapeutics, Inc.$378
- Vanda Pharmaceuticals Inc.$93
- Alkermes, Inc.$66
- Neurocrine Biosciences, Inc.$33
- plus $57 from 3 others
What the payments were for
- Speaking & faculty fees$23,42580%
- Travel & lodging$4,09614%
- Food & beverage$1,8216%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 58 | $28,210 |
| Johnson & Johnson | 8 | $516 |
| Axsome Therapeutics, Inc. | 8 | $378 |
| Vanda Pharmaceuticals Inc. | 1 | $93 |
| Alkermes, Inc. | 3 | $66 |
| Neurocrine Biosciences, Inc. | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$27,627
- INVEGA SUSTENNA$242
- Auvelity$236
How this compares
$29,354 in reported general payments places this provider in the 95th percentile of 407 psychiatric/mental health providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 20 | $6,545 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 15 | $1,481 |
| Naltrexone Hcl | 17 | $663 |
| Aripiprazole | 15 | $411 |
| Duloxetine Hcl | 21 | $313 |
| Bupropion XlBupropion Hcl | 36 | $309 |
| Trazodone Hcl | 27 | $262 |
| Clonazepam | 37 | $241 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 12 | $203 |
| Fluoxetine Hcl | 19 | $195 |
| Hydroxyzine Pamoate | 19 | $121 |
| Olanzapine | 17 | $99 |
| Clonidine Hcl | 11 | $79 |
| Lamotrigine | 30 | $78 |
| Quetiapine Fumarate | 16 | $34 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Moorhead
- Naomi KoenigSandstone$8K
- Dana BageonWayzata$7K
- Jill ScottAnoka$5K
- Holly WillisMinneapolis$5K
- Gerard BalanMinneapolis$5K
- Hilary BreedonShakopee$3K
- Tina AlexanderEdina$3K
- Twilla OskeyBaxter$3K
- Sara OckerCambridge$3K
- Patrick DixonAnoka$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.